Morocco Pharmaceuticals and Healthcare Report Q1 2016

102 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: The Moroccan government’s decision to reimburse generic Sovaldi (sofosbuvir) along with the
incorporation of students into it medical coverage scheme highlights its commitment to increasing the
population’s access to healthcare – a positive to drugmakers. However, in the long-term, the uncertainty
surrounding drug prices will still remain an issue for drugmakers, hindering the country’s attractiveness to
drug companies whose portfolios contain high value drugs.
Headline Expenditure Projections
? Pharmaceuticals: MAD12.52bn (USD1.49bn) in 2014 to MAD13.39bn (USD1.40bn) in 2015; +6.8% in
local currency terms and -5.9% in US dollar terms. Forecast revised upwards from last quarter.
? Healthcare: MAD55.63bn (USD6.61bn) in 2014 to MAD59.35bn (USD6.21bn) in 2015; +6.7% in local
currency terms and -6.1% in US dollar terms. Forecast revised downwards from last quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Morocco 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Morocco 2011-2019) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019) 26
OTC Drug Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Morocco 2011-2019) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Morocco 2013-2019) 33
Table: Pharmaceutical Trade Data And Forecasts local currency (Morocco 2013-2019) 33
Pharmaceuticals & Healthcare Risk/Reward Index 34
Middle East and Africa Risk/Reward Index - Q1 2016 34
Morocco Risk/ Reward Index 42
Rewards 42
Risks 43
Market Overview 45
Epidemiology 45
Healthcare Sector 48
Table: Healthcare Resources (Morocco 2009-2014) 52
Table: Healthcare Personnel (Morocco 2009-2014) 53
Table: Healthcare Activity (Morocco 2009-2014) 53
Healthcare Insurance 53
Recent Health Insurance Developments 55
Research & Development 58
Clinical Trials 59
Regulatory Review 60
Intellectual Property Regime 61
Pricing Regime 61
Reimbursement Regime 64
Competitive Landscape 67
Pharmaceutical Industry 67
Table: Morocco's Select Pharmaceutical Industry Indicators 67
Table: Members Of MIS, 2011 68
Table: Members Of AMIP, 2011 69
Domestic Pharmaceutical sector 69
Foreign Pharmaceutical Companies 70
Table: Multinational Market Activity 73
Pharmaceutical Wholesale 73
Pharmaceutical Retail 74
Company Profile 76
GlaxoSmithKline 76
Laprophan 78
Pfizer 81
Sanofi 84
Sothema 88
Demographic Forecast 91
Demographic Outlook 91
Table: Population Headline Indicators (Morocco 1990-2025) 92
Table: Key Population Ratios (Morocco 1990-2025) 92
Table: Urban/Rural Population & Life Expectancy (Morocco 1990-2025) 93
Table: Population By Age Group (Morocco 1990-2025) 93
Table: Population By Age Group % (Morocco 1990-2025) 94
Glossary 96
Methodology 98
Pharmaceutical Expenditure Forecast Model 98
Healthcare Expenditure Forecast Model 98
Notes On Methodology 99
Risk/Reward Index Methodology 100
Index Overview 101
Table: Pharmaceutical Risk/Reward Index Indicators 101
Indicator Weightings 102

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Morocco 2013-2019)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Morocco 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
Table: Pharmaceutical Trade Data And Forecasts (Morocco 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Morocco 2013-2019)
Table: Healthcare Resources (Morocco 2009-2014)
Table: Healthcare Personnel (Morocco 2009-2014)
Table: Healthcare Activity (Morocco 2009-2014)
Table: Morocco's Select Pharmaceutical Industry Indicators
Table: Members Of MIS, 2011
Table: Members Of AMIP, 2011
Table: Multinational Market Activity
Table: Population Headline Indicators (Morocco 1990-2025)
Table: Key Population Ratios (Morocco 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Morocco 1990-2025)
Table: Population By Age Group (Morocco 1990-2025)
Table: Population By Age Group % (Morocco 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Morocco Pharmaceuticals and Healthcare Report Q2 2015BMI View: A new wave of drug price cuts in Morocco and the implementation of the final stage of its universal healthcare coverage programme will see an improvement in the population's access to medicines. While increasing access to medicines is positive for drugmakers, we highlight that the Moroccan pharmaceutical market will become increasingly challenging for innovative drugmakers due to the lack of clarity regarding further medicine price cuts and the increasing market share of […]
  • Morocco Pharmaceuticals and Healthcare Report Q2 2016BMI View: We hold an optimistic outlook for the Moroccan pharmaceutical market despite the economic slowdown over 2016. We expect the government's increasing efforts to improve healthcare coverage coupled with the country's growing non-communicable disease burden will drive the demand for medicines in long-term. A major downside risk to our forecast is the uncertainty surrounding drug prices as a result of price cuts and increased taxation on medicines in recent years, which will […]
  • Sweden Pharmaceuticals and Healthcare Report Q4 2014BMI View: As Sweden's population grows older and demands for healthcare provision increase, the government is facing a concerning scenario of rapidly increasing expenditure on medical services. Restricting innovative drugmaker revenue streams while increasing the use of affordable generic medicines offers a partial solution to the problem, as does encouraging the consumption of older medicines over newer, higher-value medicines. Headline Expenditure Projections ? Pharmaceuticals: […]
  • Switzerland Pharmaceuticals and Healthcare Report Q3 2015BMI View: The preference for patented drugs over low-value generic medicines by patients and prescribers in Switzerland will drive the government to continue to enforce measures that restrict growth in innovative medicine sales - particularly as the ageing population will boost the demand for long-term medicines. This will include price cuts on patented medicines as well as a push towards the greater promotion of lowervalue generic medicines. Headline Expenditure Projections ? […]
  • Netherlands Pharmaceuticals and Healthcare Report Q1 2016BMI View: The Netherlands has a well-developed healthcare system due to generous public expenditure over the years. Despite newly introduced cost-cutting measures, government spending on healthcare will continue to increase in local currency terms, especially as the wider eurozone recovers. However, the country's aging population will put pressure on government finances over the longer-term, inevitably leading to further price caps on medicines. Headline Expenditure Projections ? […]